Laimi Pharmaceuticals receives approval for supplemental application for naloxone hydrochloride injection
May 14, 2025
Source: drugdu
77
On May 12, Laimei Pharmaceutical issued an announcement that recently, the company received the "Notice of Approval of Drug Supplementary Application" approved and issued by the State Food and Drug Administration for two specifications of naloxone hydrochloride injection: 1ml:1mg and 2ml:2mg.
Naloxone hydrochloride injection is an opioid receptor antagonist, mainly used for the antagonism of respiratory depression after opioid combined anesthesia and the treatment of opioid overdose.
According to Yaorongyun data, the market sales of the drug in 2022, 2023 and the first half of 2024 were 420 million yuan, 559 million yuan and 264 million yuan respectively. The approval of this supplementary application means that the company can add new specifications of products, while changing the excipients and production processes in the prescription, further enhancing the market adaptability of the product.
In the first quarter of 2025, Laimi Pharmaceutical achieved revenue of 198 million yuan and a net profit attributable to shareholders of the parent company of -13.78 million yuan.
https://finance.eastmoney.com/a/202505123402070839.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Which Strength Training Method Is Best for You? Experts Break Down the Options July 9, 2025
- Is One Type of Water Healthier Than Another? Here’s What Experts Say July 9, 2025
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
